Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
J Med Econ
; 25(1): 741-749, 2022.
Article
in En
| MEDLINE
| ID: mdl-35615978
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Antirheumatic Agents
/
COVID-19
Type of study:
Health_economic_evaluation
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Aspects:
Implementation_research
Limits:
Adult
/
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
J Med Econ
Journal subject:
SERVICOS DE SAUDE
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: